High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden

Jonas Björk\textsuperscript{a,b}, Malin Inghammar\textsuperscript{c}, Mahnaz Moghaddassi\textsuperscript{d}, Magnus Rasmussen\textsuperscript{c}, Ulf Malmqvist\textsuperscript{b} and Fredrik Kahn\textsuperscript{c}\textsuperscript{d}

\textsuperscript{a}Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden; \textsuperscript{b}Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden; \textsuperscript{c}Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden; \textsuperscript{d}Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

\section*{ABSTRACT}

\textbf{Background:} Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings.

\textbf{Methods:} A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease.

\textbf{Results:} The estimated vaccine effectiveness in preventing infection \( \geq 7 \) days after second dose was 86\% (95\% CI 72–94\%) but only 42\% (95\% CI 14–63\%) \( \geq 14 \) days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91\% (95\% CI 85–94\%) effectiveness against new infection among the unvaccinated.

\textbf{Conclusion:} A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.

\section*{KEYWORDS}
SARS-CoV2, COVID-19 vaccines, COVID-19 testing, vaccine effectiveness

\section*{ARTICLE HISTORY}
Received 12 June 2021
Revised 3 September 2021
Accepted 13 September 2021

\section*{CONTACT}
Fredrik Kahn
fredrik.kahn@med.lu.se
Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden, Halsogatan 3, Lund SE-221 85, Sweden

\section*{ARTICLE HISTORY}
Received 12 June 2021
Revised 3 September 2021
Accepted 13 September 2021

\section*{CONTACT}
Fredrik Kahn
fredrik.kahn@med.lu.se
Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden, Halsogatan 3, Lund SE-221 85, Sweden

\section*{ARTICLE HISTORY}
Received 12 June 2021
Revised 3 September 2021
Accepted 13 September 2021

\section*{CONTACT}
Fredrik Kahn
fredrik.kahn@med.lu.se
Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden, Halsogatan 3, Lund SE-221 85, Sweden

\section*{ARTICLE HISTORY}
Received 12 June 2021
Revised 3 September 2021
Accepted 13 September 2021

\section*{CONTACT}
Fredrik Kahn
fredrik.kahn@med.lu.se
Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden, Halsogatan 3, Lund SE-221 85, Sweden

\section*{ARTICLE HISTORY}
Received 12 June 2021
Revised 3 September 2021
Accepted 13 September 2021

\section*{CONTACT}
Fredrik Kahn
fredrik.kahn@med.lu.se
Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden, Halsogatan 3, Lund SE-221 85, Sweden

\section*{CONTACT}
Fredrik Kahn
fredrik.kahn@med.lu.se
Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden, Halsogatan 3, Lund SE-221 85, Sweden
**Introduction**

There has been a very rapid development of vaccines against SARS-CoV-2 and mass vaccination campaigns have been launched worldwide [1,2]. To date, four different vaccines have been licenced in the European Union; BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech), mRNA-1273 (Moderna Vaccine), ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2-S (Jansen). In Skåne, a county in Southern Sweden with approximately 1.4 million inhabitants, the vaccination campaign started on 27 December 2020. The first to be vaccinated were nursing home residents and their caregivers as well as frontline health care workers. The aim of this study was to evaluate vaccine effectiveness (VE) of the BNT16b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in preventing SARS-CoV-2 infection in people of working age.

**Materials and methods**

**Data sources**

This cohort study was based on registers kept for administrative purposes at the Skåne county council, Sweden. Data sources were the total population register used for individual-level data on residency and vital status, and health care registers used for individual-level data on vaccinations and positive COVID-19 test results. Linkage between the different data sources was facilitated using the personal identification number assigned to all Swedish citizens at birth or immigration.

**Study cohort**

The study cohort included all persons aged 18–64 years residing in Skåne county, Sweden, on 27 December 2020 when vaccinations started. The cohort was followed until 28 February 2021. Data on vaccination including type of vaccine and dose were linked to the cohort, together with data on prior positive COVID-19 tests at any time point from March 2020 until 26 December 2020. Individuals who during follow up were vaccinated with other COVID-19 vaccines than BNT16b2 mRNA were excluded at baseline due to too small numbers to permit evaluation (1.0% of the population). Individuals moving out from the region during follow up were censored on the date of relocation.

**Outcomes**

The primary outcome was the first positive SARS-CoV2 test result received from 27 December 2020 to 28 February 2021, hereafter called SARS-CoV-2-infection. During the study period, the Regional Centre for Disease Control recommended individuals of >6 years old with symptoms of COVID-19 to get tested. Additionally, test recommendations were from 21 January 2021 given to persons living in the same household as a person with a confirmed infection, irrespective of own symptoms, five days after the index case. Sampling was performed mainly from nasopharynx and analysed by RT-PCR at the Regional Laboratory of Clinical Microbiology or through a combined sampling from pharynx, nose and saliva through RT-PCR at laboratories assigned by the Swedish Board of Health and Welfare: Dynamic Code AB, Linköping, Sweden and Eurofins LifeCodexx GmbH, Germany. Moreover, some patients and health care workers were tested using antigen tests (PANBIOTM, Abbots) from nasopharynx samples, within both primary and secondary care. Result from all diagnostic modalities and laboratories were available for the study. As secondary outcome, we used death with COVID-19, defined as death within 30 days of a positive test.

**Statistical analysis**

Statistical analyses were conducted in Stata SE 14.2 (Stata Corp.) and IBM SPSS Statistics 26 (SPSS Corp.). The number of the positive COVID-19 tests was calculated in relation to person-weeks of follow up, separately for unvaccinated and vaccinated follow up time, and stratified according to (i) no dose or 0–13 days after the first dose, (ii) at least 14 days after the first dose but before second dose, (iii) 0–6 days after the date of the second dose, (iv) at least 7 days after the second dose. To account for variations in community spread during follow up, the counting of cases and person-weeks was done separately in four two-week periods (period 1: Dec 27–Jan 17, period 2: Jan 18–31, period 3: Feb 1–14 and period 4: Feb 15–28). We estimated the VE overall and stratified by sex among individuals with no prior positive test at baseline as \( \frac{IRR}{1} \) together with 95% confidence interval (CI), where IRR represents the incidence rate ratio contrasting unvaccinated with vaccinated person-time. Main VE results were reported for period 4 with the longest follow up, and we also present results for period 3 as comparison whereas only incidence rates are presented for the two prior periods where no effect can be assumed. As a further reference, we calculated effectiveness associated with a prior positive test at baseline. All statistical analyses were weighted to
account for differences in sex and age distribution (five groups: 18–44, 45–49, 50–54, 55–59 and 60–64 years old) among vaccinated and unvaccinated.

Results

The study cohort comprised 805,741 individuals on 27 December 2020, of whom 26,587 (3.3%) received at least one dose of the BNT16b2 mRNA vaccine before 28 February 2021 (Table 1). The incidence of SARS-CoV-2 infection in the study cohort peaked in mid-January 2021 with a weekly incidence of 880 cases per 100,000 individuals, and then decreased gradually to 250 cases per 100,000 individuals in the last week of February. The vaccinated cohort had a higher proportion of females (80% vs. 52%) and was older (median age 47 vs. 40 years) than the unvaccinated cohort. The median time between dose 1 and dose 2 was 28 days and 99% of the vaccinated had an interval of ≥21 days between the doses. There were 8 observed cases of SARS-CoV-2 infection 7 days or more after the second dose among subjects with no prior positive test during period 4 (Feb 15–28), whereas 56 cases were expected if they have had the same incidence rated as the unvaccinated during that period. Thus, the estimated VE in preventing infection 7 days or more after second dose among subjects with no prior positive test was 86% (95% CI 72–94%) during period 4 (Table 2 and Figure 1). Similar but more statistically uncertain VE (93%; 95% CI 59–100%) was observed in period 3 (Figure 1 and Supplementary Table S1). VE was similar among females and males, but more statistically uncertain among males due to fewer vaccinated (Supplementary Table S2). No deaths within 30 days of a positive test were observed.

Table 1. Baseline characteristics of the study cohort on 27 December 2020 when COVID-19 vaccination started, stratified by vaccination status on 28 February 2021.

|                   | Vaccinated (n = 26,587) | Unvaccinated (n = 779,154) | Uptake (% of total) (3.3) |
|-------------------|------------------------|-----------------------------|---------------------------|
| Sex, n (%)        |                        |                             |                           |
| Female            | 21,274 (80.0)          | 404,808 (52.0)              | 5.4                       |
| Male              | 5,313 (20.0)           | 374,346 (48.0)              | 1.3                       |
| Age by sex, n (%) |                        |                             |                           |
| Female 18–44      | 8,947 (33.7)           | 223,877 (28.7)              | 3.8                       |
| 45–49             | 2,711 (10.2)           | 40,405 (5.2)                | 6.3                       |
| 50–54             | 3,097 (11.6)           | 39,870 (5.1)                | 7.2                       |
| 55–59             | 3,572 (13.4)           | 37,283 (4.8)                | 8.7                       |
| 60–64             | 2,947 (11.1)           | 32,911 (4.2)                | 8.2                       |
| Male 18–44        | 2,854 (10.7)           | 239,332 (30.7)              | 1.2                       |
| 45–49             | 541 (2.0)              | 44,580 (5.7)                | 1.2                       |
| 50–54             | 554 (2.1)              | 43,876 (5.6)                | 1.2                       |
| 55–59             | 644 (2.4)              | 41,427 (5.3)                | 1.5                       |
| 60–64             | 720 (2.7)              | 35,593 (4.6)                | 2.0                       |
| Country of birth  |                        |                             |                           |
| Sweden            | 20,725 (78.0)          | 547,873 (70.3)              | 3.6                       |
| Abroad            | 5,862 (22.0)           | 231,281 (29.7)              | 2.5                       |
| Civil status      |                        |                             |                           |
| Unmarried         | 10,088 (37.9)          | 380,434 (48.8)              | 2.6                       |
| Married           | 12,066 (45.4)          | 307,642 (39.5)              | 3.8                       |
| Divorced          | 4,065 (15.3)           | 85,723 (11.0)               | 4.5                       |
| Widow/widower     | 368 (1.4)              | 5,355 (0.7)                 | 6.4                       |
| Positive SARS-CoV-2 test before 27 December 2020 | 2,660 (10.0) | 36,740 (4.7) | 6.8 |

Table 2. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 4 (15–28 February 2021).

|                  | Cases, n | Person-time, weeks | Incidence (95% CI) a | Effectiveness, % (95% CI) |
|------------------|----------|--------------------|----------------------|---------------------------|
| No prior positive test |          |                    |                      |                           |
| Unvaccinated or before 1st dose | 4,155    | 1,414,660          | 294 (285–303)        | Reference b               |
| 1st dose, day 0–13 | 9        | 2,260              | 398 (138–658)        | Not evaluated              |
| 1st dose, day 14–25 | 25       | 14,690             | 170 (103–237)        | 42 (14–63)                 |
| 2nd dose, day 0–6  | 10       | 8,537              | 117 (45–190)         | 60 (27–81)                 |
| 2nd dose, day 7–13 | 8        | 19,088             | 42 (13–71)           | 86 (72–94)                 |
| Prior positive test |          |                    |                      |                           |
| Unvaccinated or before 1st dose | 21       | 75,399             | 28 (16–40)           | 91 (85–94)                 |

aCases per 100,000 persons and week (95% confidence interval). Results from statistical analysis were weighted with respect to sex and age distribution of the vaccinated cohort.

bReference category in the calculation of vaccine effectiveness.

cThe number of vaccinated with prior positive test was too few to permit evaluation of vaccine effectiveness.
among the vaccinated (Supplementary Table S3). The corresponding case fatality risk was 0.1% among the unvaccinated (27 deaths among 25,970 cases that were followed 30 days). Having a prior positive test was associated with 91% (95% CI 85–94%) effectiveness against new infection among the unvaccinated during period 4 (Table 2). This protective effect was similarly high during period 3 (Supplementary Table S1), and still high when restricting the analysis to individuals with a prior positive test more than three months before baseline (83%, 95% CI 51–97%; not in tables).

**Discussion**

The most salient finding was the satisfactory VE in preventing SARS-CoV-2 infection seven days or more after the second dose of the BNT16b2 mRNA vaccine, observed in a working age population. A major strength of the study was the rapid evaluation of vaccine effectiveness in a real-world Scandinavian setting with substantial and prevailing community spread of the virus. The circulation of SARS-CoV-2 in the region was among the highest in Europe during the study period with incidence rates between 300 and 900 new cases per week and 100,000 population, why the vaccinated cohort most likely had considerable exposure to the virus during follow up.

A limitation was the short follow up time, and the current lack of data to evaluate effects on disease severity and hospitalisations and effects of specific virus variants. Surveillance data compiled by the Public Health Agency of Sweden suggest that 32–50% of the positive tests were of the B.1.1.7 variant in the study region during the last follow up period [3]. We also lacked data on disease history and co-existing conditions in the study population, preventing a detailed stratification (or matching) of vaccinated and unvaccinated beyond sex, age and follow up period. The main reason for vaccination in the study cohort was working in the health care sector with frontline personnel given highest priority, but individuals aged up to 64 years who were vaccinated due to their residence in special homes were also included. As we could not account for differences in health related to occupational status and residence across cohorts, we decided not to evaluate effects on all-cause mortality. However, we observed no deaths related to COVID-19 among the vaccinated, but it should be noted that the case fatality risk was low also among unvaccinated in this working age cohort. The median interval between doses was in this study 28 days and thus a bit longer than the 21 days in the clinical trials and to what was recommended. This was most likely due to a relative shortage of vaccine. Since only persons without a previously verified SARS-CoV-2 infection was included in the cohort when estimating VE we minimised the risk of detecting persistent RNA shedding. However, we cannot exclude the possibility that a person with a previously asymptomatic infection with continued RNA shedding gets tested again and thus adjudicated as a new case. As a final limitation, we may have some bias in the estimated VE due to unknown prior infections, especially as COVID-19 testing was limited in this population during the spring 2020.

Several reports on VE of the BNT162b2 mRNA vaccine have emerged since the launch of large vaccination campaigns in many parts of the world. Although we estimated the VE after 14 days after the first dose, we also studied the effect 0–6 days after the second dose with a comparably low estimated VE (60%) where the effect is probably still due to the first dose. A cohort study in health care workers in UK demonstrated a VE against SARS-CoV-2 infection after first dose that was higher than in our study (72% after 21 days), whereas they found similar VE as we after second dose (86% after 7 days) [4]. Other studies have also reported higher VE after the first dose [5,6], and reduced risk of severe COVID-19 that required hospitalisation [7]. However, a cohort study from Israel with detailed matching on demographic and clinical characteristics in a diverse population showed similar evolution of VE after first and second dose as in our study when evaluated against symptomatic infection (57% 14–20 days after first dose and 94% 7 days after second dose [8].

The suggested high protection (91%–94% depending on level of community spread) by a previous infection in
our study is in line with recently published studies. A study from Denmark suggested an overall protection against reinfection of 81% during the second surge of the COVID-19 epidemic, but with markedly diminishing protection of individuals ≥65 years old [9]. Among healthcare workers in UK the estimated protection of a previous infection was 94% against a probable or possible symptomatic infection and 83% against all probable and possible infections (our calculations based on reported odds ratios) [10].

As our results suggest that vaccine effectiveness may not be satisfactory until seven days after the second dose, it is prudent to inform the public about the importance of maintaining social distancing and complying with other recommendations until full vaccine effect can be expected. Compliance with recommendations is likely to be especially important in regions where the exposure to the virus is still considerable. Another aspect of the present findings, especially when making priorities in the vaccination programs for the general population, is the strong protective effect associated with documented prior infection. It is important to continue to monitor VE for longer periods and to compare VE of different vaccines, and also carefully monitoring risk of adverse events. Sweden, with its combination of register infrastructure for population studies and prevailing community spread of the SARS-CoV-2 virus, constitutes a suitable setting for such further studies.

Conclusion

In conclusion, we found a vaccine effectiveness of 86% in preventing infection 7 days or more after second dose of BNT16b2 mRNA vaccine, in adults of working age during a period of high circulation of SARS-CoV-2. The observed vaccine effectiveness was not satisfactory after a first dose only.

Acknowledgments

Cecilia Åkesson-Kotsaris, Paul Söderholm and Helena Hallefjord, Clinical Studies Sweden, for excellence in bringing the data infrastructure in place. Susann Ullén, Clinical Studies Sweden, for statistical advice.

Ethics and permissions

Ethical approval was obtained from the Swedish Ethical Review Authority (2021-00059).

Author contributions

All authors conceived and designed the study, analysed and interpreted the results. UM, JB and MM acquired data, JB and MM conducted the statistical analyses. JB, FK, and MI drafted the manuscript. All authors critically revised the manuscript and approved the final version for submission. FK supervised the study and is the guarantor.

Disclosure statement

FK has on one occasion in 2019 held a lecture on vaccines for general practitioners sponsored by Sanofi Pasteur. All other authors declare no conflicts of interest, no support or financial relationship with any organisation or other activities with any influence on the submitted work.

Funding

This study was supported by an internal grant for thematic collaboration initiatives at Lund University held by JB, and by Swedish Research Council [VR; grant number 2019-00198]. FK is supported by grants from the Swedish Research Council and Governmental Funds for Clinical Research (ALF). The funders played no role in the design of the study, data collection or analysis, decision to publish, or preparation of the manuscript.

ORCID

Jonas Björk http://orcid.org/0000-0003-1883-2000
Malin Inghammar http://orcid.org/0000-0003-2995-1312
Mahnaz Moghaddassi http://orcid.org/0000-0002-0844-4736
Magnus Rasmussen http://orcid.org/0000-0003-1588-5473
Fredrik Kahn http://orcid.org/0000-0001-5566-6350

References

[1] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
[2] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
[3] Statistik om SARS-CoV-2 virusvarianter av särskild betydelse (in Swedish). Stockholm: Public Health Agency of Sweden; 2021.
[4] Hall VJ, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine against infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN study). SSRN 2021.
[5] Amit S, Regev-Yochay G, Afek A, et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875–877.
[6] Hunter PR, Birdnard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel. medRxiv 2021:2021.02.01.21250957.
[7] Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. SSRN 2021.

[8] Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384:1412–1423.

[9] Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397(10280):1204–1212.

[10] Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multicentre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv 2021. DOI:10.1101/2021.01.13.21249642